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Abstract: Anti-depressant (AD) prescribing rose in several countries worldwide over the last 20 years. Some concerns 
have been raised over the fact that AD use, mainly Selective Serotonin Reuptake Inhibitors (SSRI) may increase the risk 
of suicide. AD consumption and suicide rates data in Emilia-Romagna region, Italy have been extracted from regional 
government databases on AD prescribing and suicide rates, from 1999 to 2008. A statistical model using ordinary least 
squares linear regression was employed. The overall suicide rates decreased during the period under examination, in spite 
of the observed exponential increase in use of ADs. Despite the doubling in prescribing of SSRI and newer ADs in recent 
years, there continues to be no negative impact on suicide rates in Emilia Romagna. 
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INTRODUCTION 
Anti-depressant (AD) prescribing rose in several   
countries worldwide over the last 20 years [1], mainly after 
the introduction of Selective Serotonin Reuptake Inhibitors 
[1, 2]. This increase may be the result of better treatment and 
recognition of depression [1]. There is some evidence that 
treating more depressed patients with AD might prevent   
suicide [3]. However, some concerns have been raised over 
the fact that AD use, mainly Selective Serotonin Reuptake 
Inhibitors (SSRI) may increase the risk of suicide [4]. Eco-
logical studies showed some evidence that more widespread 
AD use corresponds to a decrease in suicide rates [1], al-
though this finding is disputed [5]. A meta-analysis pub-
lished in 2009 [6] showed that the risk in suicidality associ-
ated with use of antidepressants strongly depends on age, 
with a higher risk in adults aged 25 years of age or under, a 
reduced risk of suicidality among people aged 65 and older, 
and a possibly protective effect in adults aged 25 to 64 years.  
The aim of this study is to investigate the trend in AD 
prescribing and deaths by suicide in Emilia Romagna, a large 
Italian region, with a view to understanding how the pattern 
of AD sale is related to suicide.  
MATERIALS AND METHODOLOGY 
Emilia-Romagna is a northern Italian region with a   
population of about 4.4 million people [7]. It has an area of 
22446 km
2.  
Data concerning suicide rates based on ICD-IX   
classification (E950-E959) [8], were collected by the SA-
LUTER database [9]. This is the official internet site for the 
Regional Government-funded statistical office on health-   
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related statistics for Emilia-Romagna region. The rates were  
age-standardized per 100000 population by the statistical 
office, with the direct method, based on the 1998 resident 
population. Rates for males and females were extracted. Data 
are available from 1999 to 2008. No data have been released 
after 2008.  
AD prescribing data were collected from the official 
government-funded CREVIF database [10]. This office   
collects data on all medication prescribed by the Italian   
National Health Service in Emilia-Romagna region. Every 
year the CREVIF issues a report outlining the Defined Daily 
Doses (DDD)/1000 population/day (DDDM) for each   
category or subcategory of medication, which is available 
on-line [10]. Data were not divided by age or sex. The DDD 
is the international unit of drug utilisation approved by the 
World Health Organisation for drug use studies [11].   
The DDD is a theoretical unit of measurement defined as the 
assumed average maintenance daily dose for a drug, used for 
its main indication in adults. The DDDM indicates how 
many people per 1,000 of the population have in theory   
received a standard dose (i.e. the DDD) of a particular   
medication or category of medication daily. The ADs were 
aggregated by CREVIF into three categories: SSRI   
(fluoxetine, fluvoxamine, citalopram, escitalopram,   
sertraline, paroxetine), Tryciclic ADs (TCA), and Others 
(Mianserin, Trazodone, Mirtazapine, Venlafaxine, Reboxet-
ine, Duloxetine). Data were available from 1999 to 2008. 
There is no data after 2008.  
A statistical model using ordinary least squares linear   
regression was employed, based on the model developed by 
Preti and Miotto [12]. The model was used in the present 
study to test for changes over time in suicide rates. Rates 
were the dependent variable and years were the independent 
variable. Linear regression analysis of rates over 10 years 
(1999-2008) was performed. A two-tailed t-test was also 
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SPSS for Windows version 19 has been used to perform 
all the calculations.  
RESULTS 
Results on AD prescribing and suicides are shown on 
Fig. (1).  
The analysis of AD drug prescribing revealed that there 
has been a marked increase in the use of SSRI. The DDDM 
for SSRI increased from 1.9 in 1999 to 31.9 in 2008, more 
than 15-fold increase. DDDM for TCA, on the other hand, 
slightly decreased from 1.9 in 1999 to 1.5 in 2008. A nearly 
5-fold increase in the prescription of other ADs has also been 
observed between 1999 and 2008, with a DDDM increasing 
from 1.5 in 1999 to 7.3 in 2008. Standardized suicide rates 
decreased in males from 16.70 in 1999 to 12.69 in 2008. In 
females, standardized suicide rates decreased from 6.15 in 
1999 to 4.61 in 2008. The Linear Regression Model showed 
that there has been a slow but progressive decrease in suicide 
rates for males (slope= -0.440, 95% Confidence   
Interval= -0.581 to -0.299, Standard Error= 0.061, Adj R
2= 
0.850,F=51.99, p= 0.0001) and for females (slope= -0.199, 
95% Confidence Interval= -0.340 to -0.057, Standard Error= 
0.061, Adj R
2= 0.567,F=10.50, p= 0.012).  
DISCUSSION 
The main finding of this study is that the overall suicide 
rates decreased during the period under examination, in spite 
of the observed exponential increase in use of ADs. 
Our analysis showed that despite the doubling in pre-
scribing of SSRI and newer ADs in recent years, there con-
tinues to be no negative impact on suicide rates in Emilia 
Romagna. If this findings were consistent to Healy’s and 
colleagues’ [4],
 prediction of an increase in suicide by SSRI, 
there would have been a marked increase in suicide rates, 
which did not happen. Also, Khan and colleagues showed 
that SSRI do not induce suicide more than other AD or even 
placebo [13]. Our findings are more in line with the data 
examined by Isaacson and colleagues for Europe and world-
wide [1],
 where suicide rates showed an opposite trend to 
AD prescribing. If we consider the trend of suicides in Italy 
we notice that there has been a decrease in rates even before 
the appearance of SSRI in the Italian market. Guaiana and 
colleagues [14] found that there was an overall decline in 
suicide rates in Italy from 1986 to 1996, both in males and in 
females. However, suicides rates markedly declined among 
elderly of both sexes and increased in males aged 15-24 and 
25-44. When suicide rates were compared to antidepressant 
prescribing in Italy, it appeared that there has been an overall 
steady decline in suicide rates, between 1955 and 2000, 
which preceded the exponential increase in AD prescribing 
[2]. This decrease may be linked to earlier treatment and 
detection of mental disorders. Vichi and colleagues also ex-
amined suicide rates in Italy between 1980 and 2002 [15]. 
They concluded that the decline in suicide rates is possibly a 
consequence of the decrease in the incidence of mental dis-
orders as a result of the development of an integrated and 
community-based mental health system, which in turn may 
have led to decreased suicide rates. AD prescribing may be 
part of this picture, as earlier detection of mental disorder 
may have to an increase in AD prescribing. Mental illness in 
general and depression in particular are a strong predictor of 
suicide [16]. Earlier detection of depression by community 
mental health services might have led to increased treatment 
with AD that, in turn, led to a decrease in suicide rates. This 
hypothesis, however suggestive, remains speculative.  
This study suffers from some obvious limitations: first of 
all, the naturalistic design makes it prone to the ecological 
fallacy, as no clear casual relationship can be established. 
Also, data on DDDM and suicides were not divided by age 
or sex. It is possible that the negative trend in suicide rates 
can be only applied to certain age groups, including the eld-
erly. It appears that people over 65 account for the majority 
of AD prescribing in Italy [17] and suicides in Italy seem to 
decline mostly in people aged 65 or more [2]. It can be pos-
sible that the decrease in suicide rates observed in Emilia-
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Romagna applies mainly to people aged 65 or older, al-
though we do not have data to confirm or refute this hy-
pothesis. Also, we assumed that all ADs are prescribed and 
used for depression. This is not entirely true, as ADs are in-
creasingly used for anxiety disorders as well, also in Italy 
[18]. Anxiety disorders are at least as prevalent as depres-
sion. Both types of disorders are highly comorbid. Our data-
base does not make it possible to find out the specific disease 
that required the prescription of the AD. However, since 
anxiety and depression are closely intermingled, the former 
being often an indicator of the severity of the latter and vice 
versa [19], this limitation does not invalidate our main con-
clusions. Finally, data on AD sale does not capture actual 
AD consumption. It is definitely possible that people who 
are prescribed AD do not take them regularly or at all.  
CONCLUSIONS 
In spite of the limitations, we can say that an increase an 
AD prescribing (particularly SSRI) has not been paralleled 
by an increase in suicide rates in Emilia-Romagna region of 
Italy. Further studies will be required to refute or corroborate 
this finding.  
ABBREVIATIONS 
AD =  Antidepressants 
DDD  =  Defined Daily Dose 
DDDM  =  Defined Daily Dose/1000/day 
SSRI  =  Selective Serotonin Reuptake Inhibitors 
TCA =  Tricyclic  Antidepressants 
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